MedPal AI plc (AIM:MPAL) co-founder and CEO Jason Drummond talked with Proactive's Stephen Gunnion about the company’s strategic expansion into the online pharmacy space following its recent listing on London’s AIM market.
Drummond explained that MedPal AI’s core product is a health app that aggregates data from multiple connected devices—such as Fitbit, Apple Watch, and Oura Ring—to provide users with personalised health insights powered by artificial intelligence. The platform now integrates pharmacy capabilities through the acquisition of Universal Pharmacy, a UK-licensed distance-selling pharmacy historically dispensing around 25,000 prescriptions per month.
Drummond said the deal enables MedPal AI to “build a seamless bridge between digital insights in the app and real-world care.” With this addition, users can now be prescribed and supplied medications—including GLP-1 weight-management treatments like Mounjaro—directly through the app.
He highlighted that more than 2.2 million UK adults (about 4% of the population) are already using GLP-1 medications, generating nearly £500 million a month in sales. The company expects to capture a share of this market as it rolls out its service.
MedPal AI has also announced partnerships with Epassi and Independent Gym Network, expanding potential access to over 30 million fitness enthusiasts. Drummond added that revenue generation is expected to begin imminently.
For more exclusive interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content.
#MedPalAI #JasonDrummond #DigitalHealth #AIHealthTech #UniversalPharmacy #AIMListing #WeightLossMedication #GLP1 #HealthApp #ProactiveInvestors
